Pursuant to 18 V.S.A.§ 4637 (Notice of Introduction of New High-Cost Prescription Drugs), Riparian, LLC, the third-party processor for Progenics Pharmaceuticals, Inc. is reporting the commercial availability of its new prescription drug AZEDRA® on June 3, 2019. AZEDRA® is a radiopharmaceutical available in two presentations:

NDC	DRUG DESCRIPTION	INTRODUCED TO MARKET DATE	WAC PRICE AT INTRODUCTION	ADDITIONAL WAC PRICE INFORMATION
71258-0015-02	AZEDRA® (iobenguane I 131) injection (30 mCi)	6/3/2019	\$9,060.00	Azedra is priced at \$302 per mCi. 71258-0015-02 is a dosimetric presentation containing 30 mCi at calibration time
71258-0015-22	AZEDRA® (iobenguane I 131) injection (337.5 mCi)	6/3/2019	\$101,925.00	Azedra is priced at \$302 per mCi. 71258-0015-02 is a therapeutic presentation containing 337.5 mCi at calibration time

The additional information requested pursuant to 18 V.S.A.§ 4637 will be provided within 30 calendar days from this notice.

## Best regards,



Don Russell
Director, Managed Services Lead

200 Sursest Drive
er drussell@historian.com
c. 4.25-441-5942